Compare CTRI & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTRI | IDYA |
|---|---|---|
| Founded | 1909 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 2024 | 2019 |
| Metric | CTRI | IDYA |
|---|---|---|
| Price | $30.50 | $29.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 16 |
| Target Price | $29.88 | ★ $52.86 |
| AVG Volume (30 Days) | ★ 1.7M | 700.3K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 412.50 | 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,982,781,000.00 | $218,710,000.00 |
| Revenue This Year | $14.62 | N/A |
| Revenue Next Year | $8.16 | $201.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 13.10 | ★ 3024.43 |
| 52 Week Low | $19.04 | $19.48 |
| 52 Week High | $42.99 | $39.28 |
| Indicator | CTRI | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 42.58 | 48.52 |
| Support Level | $27.77 | $27.66 |
| Resistance Level | $31.74 | $29.50 |
| Average True Range (ATR) | 1.32 | 1.05 |
| MACD | -0.34 | 0.23 |
| Stochastic Oscillator | 33.08 | 71.00 |
Centuri Holdings Inc is a pure-play North American utility infrastructure services company that partners with regulated utilities to maintain, upgrade and expand the energy network that powers millions of homes and businesses. Its service offerings consist of the modernization of utility infrastructure through the maintenance, retrofitting and installation of electric and natural gas distribution networks to meet current and future demands while also preparing systems for the transition to clean energy sources. Its reportable segments are: (i) U.S. Gas Utility Services (U.S. Gas); (ii) Canadian Utility Services (Canadian Operations); (iii) Union Electric Utility Services (Union Electric); and (iv) Non-Union Electric Utility Services (Non-Union Electric).
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.